CAR‑T 19 combined with reduced‑dose PD‑1 blockade therapy for treatment of refractory follicular lymphoma: A case report
Open Access
- 27 August 2019
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 18 (5), 4415-4420
- https://doi.org/10.3892/ol.2019.10783
Abstract
Anti‑CD19 chimeric antigen receptor T cell (CAR‑T) therapy has changed the typical outcomes of relapsed/refractory B‑cell leukemia and lymphoma. However, treatment effectiveness for patients with relapsed/refractory B‑cell non‑Hodgkin lymphoma has been less satisfactory compared with patients with B‑cell acute lymphoblastic leukemia. The present study described a case of refractory follicular lymphoma. A high expression of programmed cell death 1 (PD‑1) was measured on CD3+ T cells (80.90%) in peripheral blood samples obtained from the patient enrolled in this study, indicating that treatment with autologous CAR‑T 19 cell therapy may not be successful. Therefore, a therapy regimen consisting of CAR‑T 19 cells in combination with a reduced dose of nivolumab (1.5 mg/kg) for PD‑1 blockade was used. A low dose of PD‑1 blockade therapy was used to reduce the adverse effects associated with the combination of a PD‑1 inhibitor and CAR‑T 19 cells. This salvage therapy resulted in remission that lasted for >10 months.Keywords
This publication has 19 references indexed in Scilit:
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsScience Translational Medicine, 2016
- Novel immunotherapies in lymphoid malignanciesNature Reviews Clinical Oncology, 2015
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesAnnals of Oncology, 2015
- Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanomaJournal for ImmunoTherapy of Cancer, 2015
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen ReceptorJournal of Clinical Oncology, 2015
- In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human PrimatesCancer Immunology Research, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Diffuse large B-cell lymphomaCritical Reviews in Oncology/Hematology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012